Comparison of the role of 18 F-fluorodeoxyglucose PET/computed tomography and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma.
Yunus Güzel, Halil Kömek, Canan Can...
https://pubmed.ncbi.nlm.nih.gov/37114422/Actively Recruiting
Led by Aalborg University Hospital · Updated on 2026-11-02
70
Participants Needed
1
Research Sites
521 weeks
Total Duration
Researchers are evaluating a new imaging technique called Gallium-68 labelled fibroblast activation protein inhibitor FAPI PETCT to improve diagnosis and staging of pleural mesothelioma PM, a type of cancer affecting the lining of the lungs. This prospective phase 2 study will enroll 70 patients suspected of having PM who are referred for pleural biopsy. The goal is to compare the accuracy of FAPI PETCT with conventional imaging methods, including FDG PETCT, using tissue biopsy as the reference standard. The study will also explore how well FAPI PETCT can assess treatment response in patients undergoing chemotherapy or immunotherapy. Participants will receive an additional FAPI PETCT scan at initial cancer staging within four weeks of their standard FDG PETCT and before biopsy. Those who proceed with anticancer treatments will have further FAPI PETCT and FDG PETCT scans after completing 2-3 treatment cycles to evaluate changes. The study procedures are extra to routine care and will not affect patient management, with results kept blinded from patients and doctors. Throughout the study, patients will undergo imaging tests and diagnostic procedures as part of regular care, with added FAPI PETCT scans for research purposes. Researchers will monitor diagnostic performance, staging accuracy, biopsy locations, uptake values, and treatment response over periods ranging from 2 to 10 years. Safety of the FAPI tracer and long-term outcomes like survival and disease progression will also be evaluated. The study will last until 2037, with extensive follow-up planned.
CONDITIONS
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
M
Morten Bentestuen, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Aalborg University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Within 4 weeks
Participants undergo standard FDG PET/CT and an additional FAPI PET/CT scan at primary cancer staging before pleural biopsy. These scans help compare imaging techniques against biopsy results.
1 visit for additional FAPI PET/CT
Duration - After completion of 2-3 treatment cycles
For participants receiving chemotherapy or immunotherapy, additional FAPI PET/CT and FDG PET/CT scans are performed after 2-3 treatment cycles to evaluate changes in the cancer.
1 to 2 additional imaging visits
Duration - Up to 10 years
Participants are monitored for diagnostic accuracy, safety, survival, disease progression, and other outcomes over several years.
Periodic assessments at regular intervals
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Yunus Güzel, Halil Kömek, Canan Can...
https://pubmed.ncbi.nlm.nih.gov/37114422/Lukas Kessler, Felix Schwaning, Martin Metzenmacher...
https://pubmed.ncbi.nlm.nih.gov/38960716/Priscilla Guglielmo, Cinzia Crivellaro, Angelo Castello...
https://pubmed.ncbi.nlm.nih.gov/39514167/Aalborg University Hospital
Lead Sponsor